Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PW Medtech Group Ltd. ( (HK:1358) ) has shared an announcement.
PW Medtech Group Limited has announced that its subsidiary Sichuan Ruijian Medical will not proceed with a planned subsequent listing on the Beijing Stock Exchange, revising earlier plans to further list the unit following its successful quotation on China’s National Equities Exchange and Quotations platform. The decision follows a strategic review of Sichuan Ruijian Medical’s business direction and the prevailing market environment, and the voluntary termination of the listing application remains subject to approvals from Sichuan Ruijian Medical’s shareholders and the Beijing Stock Exchange, signaling a recalibration of the group’s capital markets strategy and creating a degree of uncertainty for investors awaiting that listing pathway.
The most recent analyst rating on (HK:1358) stock is a Buy with a HK$1.50 price target. To see the full list of analyst forecasts on PW Medtech Group Ltd. stock, see the HK:1358 Stock Forecast page.
More about PW Medtech Group Ltd.
PW Medtech Group Limited is a Cayman Islands-incorporated medical group listed in Hong Kong that operates in the healthcare sector, with interests in medical businesses including Sichuan Ruijian Medical. The group focuses on capital markets activities related to its healthcare assets, including listings and disposals intended to optimize its portfolio and funding structure.
Average Trading Volume: 693,114
Technical Sentiment Signal: Hold
Current Market Cap: HK$1.57B
For detailed information about 1358 stock, go to TipRanks’ Stock Analysis page.